Cortical blood flow was higher in normal subjects than in those with acute rejection
and ATN, which showed no difference.
Lower tacrolimus trough levels are associated with subsequently higher acute rejection
risk during the first 12 months after kidney transplantation.
Eight recipients presented an acute rejection
(25) Another study in Saudi Arabia, which included 165 adults, showed that patients who had transplants abroad had a significantly higher rate of acute rejection
in the first year compared to patients who had local kidney transplantation (27.9% vs.
We hypothesized that targeted depletion of the resident donor B cells within the graft may further reduce the risk of acute rejection
by limiting highly immunogenic direct antigen presentation (ref).
However, patients are at an increased risk of insufficient immunosuppression and acute rejection
. Acute rejection
in the SRTR database is based on transplant center reports.
(11) It is characterized by a mononuclear cell infiltrate around small vessels and capillaries ("acute rejection
") and/or small airways ("small airways inflammation" or "lymphocytic bronchiolitis").
Early transplant outcomes were then evaluated on the basis of the frequency of DGF and acute rejection
, as well as one-year graft and patient survival.
Two of twelve (17%) of acute rejection
episodes were confirmed by renal biopsy.
High risk patients were D+/R-, those who received induction therapy with r-ATG, and those treated for acute rejection
. These patients were monitored every other week beginning on day 21 post transplant for CMV infection using the pp65 antigenemia test.
Researchers presented findings at the recent AACC annual meeting that DNA found circulating in the bloodstream--known as cell-free DNA--can be used to identify liver transplant patients with acute rejection
with greater accuracy than conventional liver function tests.
Results: Acute rejection
was seen in 19.5% of the young age group while this rate was 16.7% in the old age group (p=0.535).
The DART study (Circulating Donor-Derived Cell-Free DNA in blood for diagnosing Acute Rejection
in Kidney Transplant Recipients) (NCT02424227) is a prospective, observational clinical study designed to collect prospective data on levels of dd-cfDNA in subjects with stable function of the transplanted organ, experiencing acute organ rejection and non-rejection organ injury as well as following changes in immunosuppressive treatment.
High-strength evidence suggests that immunosuppression with low-dose CsA or TAC, in combination with adjunctive therapies, results in lower risk of acute rejection
and graft loss and improved renal function.